**Background:** The gut microbiota sits at the interface between the external environment and host cells, regulating interactions that influence health and disease. Dysbiosis has been linked to cancer, autoimmune, cardiovascular, metabolic, and neuropsychiatric disorders. Microbial metabolites—particularly short-chain fatty acids (SCFAs)—can induce epigenetic modifications (DNA methylation, histone acetylation/methylation) by serving as substrates, cofactors, or inhibitors of epigenetic enzymes. This review hypothesizes that dietary modulation of gut microbiota can be used to tune microbiota–host epigenetic interactions for health promotion and disease prevention.
**Methods:** This is a narrative review synthesizing published literature on diet–microbiota interactions, microbial metabolite production, and epigenetic mechanisms. The authors provide an overview of how various dietary patterns (Western, Mediterranean, vegan, high-fiber, high-fat, calorie-restrictive) alter gut microbial populations and their metabolic output. They then examine the biochemical requirements of epigenetic enzymes (HATs, HDACs, DNMTs, HMTs, TETs) and how microbial metabolites can modulate these enzymes. Finally, they explore therapeutic implications of the diet–microbiota–epigenetics axis.
**Key Results:** The review reports that a Western diet (rich in animal protein and saturated fats) promotes Bacteroides dominance and increases production of pro-atherogenic trimethylamine N-oxide (TMAO) and uremic toxins (indole, p-cresyl sulfate), while decreasing SCFA-producing bacteria. Conversely, a Mediterranean diet (high in fiber, polyphenols, unsaturated fats) increases Bifidobacteria, Lactobacillus, and Prevotella, enhancing production of SCFAs (butyrate, acetate, propionate) and sulforaphane. Butyrate inhibits histone deacetylases (HDACs) at millimolar concentrations, upregulating tumor suppressor genes (Fas, p21) and inducing apoptosis in cancer cells. Sulforaphane, derived from glucosinolates in cruciferous vegetables via microbial metabolism (Bacteroides thetaiotaomicron, Enterococcus faecalis, Enterococcus faecium), also inhibits HDACs and normalizes DNA methylation. Polyphenol metabolites (urolithins from ellagitannins) inhibit HATs and NF-κB signaling. TMAO activates MAPK and NF-κB pathways, induces NLRP3 inflammasome formation, increases platelet calcium release and aggregation, and promotes atherogenesis. The NAD+/NADH ratio, influenced by caloric restriction (20–40% reduction), enhances sirtuin activity. The SAM/SAH ratio, influenced by folate from diet and microbial synthesis (Bifidobacterium, Lactobacillus), affects DNMT and HMT activity.
**Clinical Implications:** The authors propose that identifying specific epigenetic targets in disease states could allow for "precision diet" interventions that modulate gut microbiota to produce desired metabolites with epigenetic effects. For example, increasing dietary fiber to boost butyrate-producing bacteria could enhance HDAC inhibition in cancer prevention; consuming cooked cruciferous vegetables with microbiota capable of converting glucosinolates to sulforaphane could provide chemoprotection; and reducing red meat intake or using resveratrol to remodel gut microbiota could lower TMAO production and cardiovascular risk. The review acknowledges limitations including phylogenetic differences between rodent models and humans, the challenge of isolating effects of individual nutrients, and the need for more human studies to establish causal links in the diet–microbiota–epigenetics axis.